AG
MCRB icon

Aperio Group’s Seres Therapeutics MCRB Stock Holding History

Aperio Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-43
Closed -$3K – 2568
2019
Q2 		$3K Buy
+43
New +$4.08K ﹤0.01% 2891
2018
Q1 		– Sell
-517
Closed -$105K – 2261
2017
Q4 		$105K Sell
517
-80
-13% -$16.4K ﹤0.01% 2205
2017
Q3 		$191K Buy
+597
New +$163K ﹤0.01% 2126

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aperio Group's MCRB Position: Q3 2019 in Review

Aperio Group sold out of Seres Therapeutics (MCRB) in Q3 2019, closing a stake of 43 shares — an estimated $3K sold.

Aperio Group first reported a position in MCRB in Q3 2017 and held it in 3 quarters. The position peaked at $191K in Q3 2017. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2019.

  • Aperio Group reported no remaining Seres Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Aperio Group sold 43 Seres Therapeutics shares in Q3 2019, an estimated $3K.
  • Aperio Group first reported a position in Seres Therapeutics in Q3 2017 and held it in 3 quarters.
  • Aperio Group's Seres Therapeutics position peaked at $191K in Q3 2017.
  • 77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.